Development of Allosteric BRAF Peptide Inhibitors Targeting the Dimer Interface of BRAF

BRAF is the most frequently mutated kinase in human cancers and is one of the major effectors of oncogenic RAS, making BRAF a target of considerable interest for anticancer drug development. Wild-type BRAF and a variety of oncogenic BRAF mutants are dependent on dimerization of the kinase domain, wh...

Ausführliche Beschreibung